Morgan Stanley Lowers Qiagen (NYSE:QGEN) Price Target to $37.00

Qiagen (NYSE:QGEN) had its target price decreased by Morgan Stanley from $39.00 to $37.00 in a research report report published on Wednesday, April 11th. Morgan Stanley currently has an overweight rating on the stock.

Separately, DZ Bank reiterated a neutral rating on shares of Qiagen in a report on Thursday, April 5th.

How to Become a New Pot Stock Millionaire

NYSE:QGEN opened at $32.79 on Wednesday. Qiagen has a 52 week low of $28.49 and a 52 week high of $36.34. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.59 and a current ratio of 5.07. The stock has a market cap of $7,534.00, a PE ratio of 25.82, a price-to-earnings-growth ratio of 2.05 and a beta of 1.02.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, January 31st. The company reported $0.43 EPS for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.01. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. The firm had revenue of $396.86 million for the quarter, compared to analysts’ expectations of $394.48 million. analysts expect that Qiagen will post 1.34 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Morgan Stanley Lowers Qiagen (NYSE:QGEN) Price Target to $37.00” was first posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with's FREE daily email newsletter.

Leave a Reply